Vyondys 53 (golodirsen) — Medical Benefit Coverage and Prior Authorization
Customize your policy alerts
Sign up for all vns_health policy alerts
Know when vns_health releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs medical-benefit coverage and prior authorization requirements for provider‑administered Vyondys 53 (golodirsen) for members with Duchenne muscular dystrophy whose DMD gene mutation is amenable to exon 53 skipping.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Initial therapy — Covered when ALL of the following are met
Covered when ALL of the following are met:
Based on coverage rationale in policy.
Concurrent administration of two exon skipping therapies for Duchenne muscular dystrophy (DMD) is not permitted. Coverage requires that the patient is not concurrently being treated with another exon skipping therapy for DMD.
The following uses or missing documentation render treatment not medically necessary or otherwise excluded: use of Vyondys 53 without documentation that the member’s DMD gene mutation is amenable to exon 53 skipping; absence of documentation confirming a stable dose of corticosteroids prior to starting therapy or a documented reason the patient is not on corticosteroids; lack of documentation of kidney function testing prior to initiation; and concurrent treatment with another exon‑skipping therapy. These conditions must be met for coverage.
Initial Therapy Criteria
inv-12: Initial therapy — initial coverage criteria for Vyondys 53
Initial coverage criteria for Vyondys 53:
VYONDYS 53 is approved under accelerated approval based on increased dystrophin production; continued approval may depend on confirmatory trials.
Coding
| J1429 | Injection, Golodirsen, 10 mg. |
Provider Actions & Authorization
Prior authorization required for golodirsen (J1429)
Coverage of golodirsen (J1429) is available under the medical benefit and is administered via buy‑and‑bill. Providers must submit the required documentation (see documentation block) to obtain prior authorization for HCPCS code J1429.
- HCPCS code: J1429 (Injection, Golodirsen, 10 mg).
- Medication billed under the medical benefit via buy‑and‑bill.
Step therapy not required
The policy does not specify any required step therapy prior to using golodirsen.
Required documentation to support authorization
Submit documentation confirming the patient’s DMD gene mutation is amenable to exon 53 skipping; documentation of a stable corticosteroid dose prior to initiation or a documented reason the patient is not on corticosteroids; and documentation of kidney function testing prior to starting therapy. Also document that the patient is not receiving another exon‑skipping therapy.
- Genetic testing confirming exon 53 amenable DMD mutation.
- Stable corticosteroid dose prior to starting therapy or documented reason for not being on corticosteroids.
- Kidney function testing prior to initiation.
- Confirmation patient is not on another exon‑skipping therapy.
Triggers for denial
Authorization or coverage may be denied if required documentation is missing or criteria are not met.
- No documentation confirming a DMD gene mutation amenable to exon 53 skipping.
- Missing documentation of a stable corticosteroid dose or a documented reason for not being on corticosteroids.
- No documentation of kidney function testing prior to initiation.
- Concurrent treatment with another exon‑skipping therapy for DMD.
Site of Care / Billing
Administer and bill via buy‑and‑bill (infusion center)
Vyondys 53 is administered in an infusion setting and billed under the medical benefit via the buy‑and‑bill process by the provider.
Definitions
Background
Vyondys 53 (golodirsen) is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD). FDA approval is for intravenous use in patients with a confirmed DMD gene mutation that is amenable to exon 53 skipping. Prior to initiating therapy, the policy requires documentation confirming the amenable mutation, confirmation of a stable corticosteroid dose prior to starting therapy or a documented reason not to be on corticosteroids, and evidence of kidney function testing prior to starting therapy. Continued coverage is conditioned on meeting these documentation and concurrence rules.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.